140
Participants
Start Date
October 26, 2022
Primary Completion Date
April 30, 2024
Study Completion Date
December 31, 2024
Semaglutide Treatment
"The participants will be provided with Semaglutide, titrated up to 14 mg. The starting dose of Semaglutide is 3 mg once daily. At week 4, the dose will be increased to 7 mg once daily. At week 8, the dose will be increased to 14 mg once daily and will be maintained at 14mg until End of Treatment (week 26). Throughout the 26 week treatment period, participants in this arm will also take one sitagliptin placebo tablet per day."
Sitagliptin 100mg
"participants will take 100mg tablet of Sitagliptin once daily, along with a semaglutide placebo pill for the duration of the 26 week treatment period"
Toronto General Hospital, Toronto
Collaborators (1)
Novo Nordisk A/S
INDUSTRY
University Health Network, Toronto
OTHER